These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 11606834)

  • 21. Blood component recalls in the United States, 1998.
    Ramsey G; Sherman LA
    Transfusion; 2000 Feb; 40(2):253-4. PubMed ID: 10686012
    [No Abstract]   [Full Text] [Related]  

  • 22. Current good manufacturing practices for blood and blood components: notification of consignees receiving blood and blood components at increased risk for transmitting HIV infection--FDA. Final rule.
    Fed Regist; 1996 Sep; 61(175):47413-23. PubMed ID: 10160337
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Blood component recalls.
    Bozzo T
    Transfusion; 1999 May; 39(5):439-41. PubMed ID: 10335990
    [No Abstract]   [Full Text] [Related]  

  • 24. [Guidelines of the German Medical Association for Therapy with Blood Components and Plasma Derivatives--an introduction. Evidence-based recommendations for the risk-benefit analysis in hemotherapy].
    Heim MU
    Anasthesiol Intensivmed Notfallmed Schmerzther; 2009 Mar; 44(3):186-97; quiz 199. PubMed ID: 19266420
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Military walking blood bank and the civilian blood service.
    Berséus O; Hervig T; Seghatchian J
    Transfus Apher Sci; 2012 Jun; 46(3):341-2. PubMed ID: 22475543
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Postdonation information and blood component retrievals: realigning blood center and hospital actions based on risk assessment.
    Eder AF; Goldman M
    Transfus Med Rev; 2014 Oct; 28(4):226-34. PubMed ID: 25311469
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Plasma components: FFP, FP24, and thawed plasma.
    Eder AF; Sebok MA
    Immunohematology; 2007; 23(4):150-7. PubMed ID: 18284305
    [No Abstract]   [Full Text] [Related]  

  • 28. Leukocyte reduction of blood components: public policy and new technology.
    Dzik S; Aubuchon J; Jeffries L; Kleinman S; Manno C; Murphy MF; Popovsky MA; Sayers M; Silberstein LE; Slichter SJ; Vamvakas EC
    Transfus Med Rev; 2000 Jan; 14(1):34-52. PubMed ID: 10669939
    [No Abstract]   [Full Text] [Related]  

  • 29. The administration of blood components: a British Society for Haematology Guideline.
    Robinson S; Harris A; Atkinson S; Atterbury C; Bolton-Maggs P; Elliott C; Hawkins T; Hazra E; Howell C; New H; Shackleton T; Shreeve K; Taylor C
    Transfus Med; 2018 Feb; 28(1):3-21. PubMed ID: 29110357
    [No Abstract]   [Full Text] [Related]  

  • 30. Reasons for moving toward a patient-centric paradigm of clinical transfusion medicine practice.
    Vamvakas EC
    Transfusion; 2013 Apr; 53(4):888-901. PubMed ID: 22882177
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Special features of blood transfusions to hematologic patients].
    Oksanen K
    Duodecim; 1998; 114(12):1233-9. PubMed ID: 11524769
    [No Abstract]   [Full Text] [Related]  

  • 32. Quality control of white cell-reduced red cells: white cell preservation and simplified counting.
    Tran K; Nakajo S; Kapoor V; Chen M; Stromberg RR
    Transfusion; 1998 May; 38(5):429-33. PubMed ID: 9633554
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Universal leukodepletion of blood components results in a significant reduction of febrile non-hemolytic but not allergic transfusion reactions.
    Pruss A; Kalus U; Radtke H; Koscielny J; Baumann-Baretti B; Balzer D; Dörner T; Salama A; Kiesewetter H
    Transfus Apher Sci; 2004 Feb; 30(1):41-6. PubMed ID: 14746820
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Biocompatibility of leukocyte removal filters during bedside leukocyte filtration of red cell concentrates.
    Gu YJ; Obster R; de Haan J; Huet RC; van Oeveren W
    Transfus Sci; 1992; 13(4):467-72. PubMed ID: 10147741
    [No Abstract]   [Full Text] [Related]  

  • 35. Guidelines on the use of irradiated blood components prepared by the British Committee for Standards in Haematology blood transfusion task force.
    Treleaven J; Gennery A; Marsh J; Norfolk D; Page L; Parker A; Saran F; Thurston J; Webb D
    Br J Haematol; 2011 Jan; 152(1):35-51. PubMed ID: 21083660
    [No Abstract]   [Full Text] [Related]  

  • 36. Consequences of Transfusing Blood Components in Patients With Trauma: A Conceptual Model.
    Jones AR; Frazier SK
    Crit Care Nurse; 2017 Apr; 37(2):18-30. PubMed ID: 28365647
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Advances in transfusion medicine: gastrointestinal bleeding.
    Oakland K; Jairath V; Murphy MF
    Transfus Med; 2018 Apr; 28(2):132-139. PubMed ID: 28737229
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Infections of the gastrointestinal system--risk of transmission with blood and blood components].
    Korsak J
    Pol Merkur Lekarski; 2007 May; 22(131):502-4. PubMed ID: 17679406
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Practical issues in neonatal transfusion practice.
    Strauss RG
    Am J Clin Pathol; 1997 Apr; 107(4 Suppl 1):S57-63. PubMed ID: 9124231
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Quality control of leucocyte-reduced blood components: overestimation of WBC content due to nucleated red blood cells.
    Fischer JC; Moog R; Giers G
    Vox Sang; 2012 Jan; 102(1):79-81. PubMed ID: 21564108
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.